Enfermedad de Paget ósea

  1. Sevilla, J. Escobar
  2. Bolívar, V. Contreras
  3. Martín, A. García
  4. Torres, M. Muñoz
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2022

Titre de la publication: Enfermedades óseas

Serie: 13

Número: 60

Pages: 3551-3559

Type: Article

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2022.06.013 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Paget's disease of bone (PDB) is the second most common metabolic bone disease and predominantly affects adult males. Various environmental factors have been described in its etiology and it is strongly conditioned by genetic variants such as sequestosome (SQSTM1). The bone undergoes an accelerated, disordered, and abnormal turnover. It can manifest in a monostotic or polyostotic manner. It tends to be asymptomatic, although it can manifest as bone pain, fractures, or through its complications, such as nerve compression or osteosarcoma. The most characteristic analytical abnormality is isolated alkaline phosphatase elevation. A plain X-ray may to be useful, although a bone scan tends to be the test of choice. At present, bisphosphonates are the first line of treatment and surgical correction may be necessary in some cases.

Références bibliographiques

  • Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M. Bone turnover markers in Paget’s disease of the bone: A systematic review and meta-analysis. Osteoporos Int. 2015; 26(7):1875-91.
  • Albagha OM. Genetics of Paget’s disease of bone. Bonekey Rep. 2015;4:756.
  • Álvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res Off J Am Soc Bone Miner Res. 1995;10(3):458-65.
  • Amilibia Cabeza E, Holgado Pérez S, Pérez Grau M, Moragues Pastor C, Roca Ribas Serdà F, Quer Agustí M. La audición en la enfermedad ósea de Paget. Acta Otorrinolaringol Esp. 2019;70(2):89-96.
  • Appelman Dijkstra NM, Papapoulos SE. Paget’s disease of bone. Best Pract Res Clin Endocrinol Metab. 2018;32(5):657-68.
  • Cook SJ, Wall C. Paget’s disease of bone: A clinical update. Aust J Gen Pract. 2021;50(1-2):23-9.
  • Corral Gudino L, Borao Cengotita Bengoa M, Del Pino Montes J, Ralston S. Epidemiology of Paget’s disease of bone: A systematic review and meta-analysis of secular changes. Bone. 2013;55(2): 347-52.
  • Corral Gudino L, del Pino Montes J, García Aparicio J, Alonso Garrido M, González Sarmiento R. Paget’s disease of bone is not associated with common polymorphisms in interleukin-6, interleukin-8 and tumor necrosis factor alpha genes. Cytokine. 2010 Dec;52(3):146-50.
  • Corral Gudino L, García Aparicio J, Sánchez González MD. Secular changes in Paget’s disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain. Osteoporos Int. 2013;24(2):443-50.
  • Corral Gudino L, Tan AJ, del Pino Montes J, Ralston SH. Bisphosphonates for Paget’s disease of bone in adults. Cochrane Database Syst Rev. 2017;12(12):CD004956.
  • Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052-62.
  • Daroszewska A, Rose L, Sarsam N, Charlesworth G, Prior A, Rose K. Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget’s disease. Dis Model Mech. 2018;11(9):dmm035576.
  • Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget’s disease and multiple myeloma. Immunol Rev. 2005; 208(1):252-66.
  • Gennari L, Rendina D, Falchetti A, Merlotti D. Paget’s disease of bone. Calcif Tissue Int. 2019;104(5):483-500.
  • Guañabens N, Rotés D, Holgado S, Gobbo M, Descalzo MÁ, Gorordo JM. Implications of a new radiological approach for the assessment of Paget disease. Calcif Tissue Int. 2012;91(6):409-15.
  • Jorge Mora A, Amhaz Escanlar S, Lois Iglesias A, Leborans Eiris S, Pino Minguez J. Surgical treatment in spine Paget’s disease: a systematic review. Eur J Orthop Surg Traumatol Orthop Traumatol. 2016;26(1): 27-30.
  • Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget’s disease of bone. Calcif Tissue Int. 2007;80(1):1-9.
  • Lucas GJ, Daroszewska A, Ralston SH. Contribution of genetic factors to the pathogenesis of Paget’s disease of bone and related disorders. J Bone Miner Res. 2006;21(S2):P31-7.
  • Makaram NS, Ralston SH. Genetic determinants of Paget’s disease of bone. Curr Osteoporos Rep. 2021;19(3):327-37.
  • Matthews BG, Afzal MA, Minor PD, Bava U, Callon KE, Pitto RP. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget’s disease. J Clin Endocrinol Metab. 2008;93(4):1398-401.
  • Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget’s disease of bone. Clin Orthop. 1984; (183):303-11.
  • Morales Piga AA, Rey Rey JS, Corres González, García Sagredo JM, López Abente G. Frequency and characteristics of familial aggregation of paget’s disease of bone. J Bone Miner Res. 2009;10(4):663-70.
  • Numan MS, Jean S, Dessay M, Gagnon E, Amiable N, Brown JP. Gene-environment interactions in Paget’s disease of bone. Joint Bone Spine. 2019;86(3):373-80.
  • Parvizi J, Klein GR, Sim FH. Surgical management of Paget’s disease of bone. J Bone Miner Res. 2006;21(S2):P75-82.
  • Polyzos SA, Makras P, Tournis S, Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone. 2019;129:115048.
  • Rabjohns EM, Hurst K, Ghosh A, Cuellar MC, Rampersad RR, Tarrant TK. Paget’s disease of bone: Osteoimmunology and osteoclast pathology. Curr Allergy Asthma Rep. 2021;21(4):23.
  • Ralston SH, Digiovine FS, Gallacher SJ, Boyle IT, Duff GW. Failure to detect paramyxovirus sequences in paget’s disease of bone using the polymerase chain reaction. J Bone Miner Res. 2009;6(11):1243-8.
  • Ralston SH. Paget’s disease of bone. N Engl J Med. 2013;368(7):644-50.
  • Reid IR. Management of Paget’s disease of bone. Osteoporos Int. 2020; 31(5):827-37.
  • Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J. A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years. J Bone Miner Res. 2011;26(9):2261-70.
  • Seitz S, Priemel M, Zustin J, Beil FT, Semler J, Minne H. Paget’s disease of bone: histologic analysis of 754 patients. J Bone Miner Res. 2009;24(1):62-9.
  • Seton M, Choi HK, Hansen MF, Sebaldt RJ, Cooper C. Analysis of environmental factors in familial versus sporadic Paget’s disease of bone-The New England Registry for Paget’s disease of bone. J Bone Miner Res. 2003;18(8):1519-24.
  • Singer FR. Human calcitonin treatment of Paget’s disease of bone. Clin Orthop. 1977;(127):86-93.
  • Singer FR, Bone HG, Hosking DJ, Lyles KW, Murad MH, Reid IR. Paget’s disease of bone: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-22.
  • Singer FR. Clinical efficacy of salmon calcitonin in Paget’s disease of bone. Calcif Tissue Int. 1991;49(S2):S7-8.
  • Tan A, Ralston SH. Clinical presentation of Paget’s disease: Evaluation of a contemporary cohort and systematic review. Calcif Tissue Int. 2014;95(5):385-92.
  • Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget’s disease. J Clin Invest. 2016;126(3):1012-22.
  • Tuck SP, Walker J. Adult Paget’s disease of bone. Clin Med. 2020;20(6): 568-71.
  • Visconti MR, Usategui Martín R, Ralston SH. Antibody response to paramyxoviruses in Paget’s disease of bone. Calcif Tissue Int. 2017;101(2):141-7.
La source de données: Dialnet